| License: Creative Commons Attribution 4.0 (6MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-407203
- DOI to cite this document:
- 10.5283/epub.40720
Abstract
Major depressive disorder is the main cause of disability worldwide with imperfect treatment options. However, novel therapeutic approaches are currently discussed, from augmentation strategies to novel treatments targeting the immune system or the microbiome-gut-brain axis. Therefore, we examined the potential beneficial effects of minocycline, a tetracycline antibiotic with pleiotropic, ...
Owner only: item control page